Literature DB >> 3293414

The probucol experience: a review of the past and a look at the future.

C J Schwartz1.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3293414     DOI： 10.1016/s0002-9149(88)80043-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  3 in total

1.  Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy.

Authors:  N Kaul; N Siveski-Iliskovic; M Hill; N Khaper; C Seneviratne; P K Singal
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

2.  Clinical and therapeutic use of probucol.

Authors:  A Berg; M W Baumstark; I Frey; M Halle; J Keul
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits.

Authors:  J H Braesen; U Beisiegel; A Niendorf
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.